Sorriso Pharmaceuticals

Sorriso's biologic therapies treat inflammatory conditions directly at the site of the disease, improving effectiveness, safety and convenience.

Market:

Sorriso’s products are designed to block multiple molecular targets that drive inflammation, as validated by rigorous research. The company’s biologic therapies are delivered orally for inflammatory bowel disease and locally in a range of other inflammatory diseases. These conditions represent a combined global market in excess of $50B.

Technology:

The Sorriso technology is based on single-domain antibodies — functional antibody fragments that Sorriso have improved to make more durable than whole antibodies — that can be linked in order to address multiple therapeutic targets. Treatments are formulated for oral delivery and other routes of local delivery, so they act directly where inflammation is damaging the body.

Advantages:

Potent, durable antibody fragments
Local delivery to inflamed tissues
Improved safety profile
Inexpensive treatment
Stable for long-term storage

Development Stage:

Sorriso has multiple products:

SOR101: Is a clinical stage asset, it has been studied in both Phase 1 and 2 clinical trials.
SOR102: Is a pre-clinical stage asset and is undergoing studies to enable a Phase 1 trial
SOR104: Is an early stage pre-clinical asset and is undergoing formulation development

Patents Pending:

PCT/EP2016/057021 anti-TNFα Vorabody SOR101
PCT/EP2017/051237 anti-IL6R Vorabody V787
PCT/GB2020/051495 anti-IL23 Vorabody SOR103 and anti-TNF/anti-IL-23 bispecific SOR102
PCT/GB2020/051496 anti-IL7R Vorabody (SOR104)

Select Publications:

Contact:

Website: www.sorrisopharma.com
Phone: (385) 342-4989
Email: info@sorrisopharma.com
LinkedIn